Rapport Therapeutics (RAPP) CEO Ceesay Abraham Sells Shares

What Happened

• Ceesay Abraham, CEO of Rapport Therapeutics, sold a total of 2,210 shares on July 27, 2026. The bulk sale was 2,203 shares at a reported weighted average price of $42.11 (proceeds $92,762) plus an additional 7 shares at $42.73 (proceeds $299), for combined proceeds of about $93,061. These are disposals (sales), not purchases.

Key Details

• Transaction date: July 27, 2026.
• Prices reported: weighted average $42.11 for 2,203 shares (actual trade prices ranged $41.66–$42.50 per footnote) and $42.73 for 7 shares.
• Total proceeds: ≈ $93,061.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Notable footnotes:
  • F1: Trades were made under a Rule 10b5-1 trading plan adopted March 27, 2026 (prearranged plan).
  • F2: The $42.11 is a weighted average; the filer can provide per-price details on request.
  • F3/F4: Some shares are held in family irrevocable trusts; the reporting person disclaims beneficial ownership of those trust shares except to the extent of any pecuniary interest.
• Timeliness: Filed July 29, 2026 for a July 27 transaction — appears filed timely (within the typical 2-business-day Section 16 reporting window).

Context

• These were sales under a pre-established 10b5-1 plan, which are often routine dispositions and do not necessarily signal a change in the insider’s view of the company. The transaction size (~$93k) is modest compared with many insider trades; avoid reading this as a definitive signal about company prospects.